Evidence map›Paper›PMID 26715683›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2016

The Protein Acyl Transferase ZDHHC21 Modulates α1 Adrenergic Receptor Function and Regulates Hemodynamics.

Ethan P Marin, Levente Jozsef, Annarita Di Lorenzo, Kara F Held, Amelia K Luciano, Jonathan Melendez, Leonard M Milstone, Heino Velazquez, William C Sessa

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Palmitoylation in cardiovascular diseases: Molecular mechanism and therapeutic potential.International journal of cardiology. Heart & vasculature · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. Insights into auto-RSC chemical biology · 2021
    Review
  15. Article
  16. Protein S-Palmitoylation and Lung Diseases.Advances in experimental medicine and biology · 2021
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ethan P MarinFrom the Section of Nephrology (E.P.M., L.J., J.M., H.V.) and Department of Dermatology (L.M.M.), Yale School of Medicine, New Haven, CT; and Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT (A.D.L., K.F.H., A.K.L., W.C.S.). ethan.marin@yale.edu.
Levente JozsefFrom the Section of Nephrology (E.P.M., L.J., J.M., H.V.) and Department of Dermatology (L.M.M.), Yale School of Medicine, New Haven, CT; and Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT (A.D.L., K.F.H., A.K.L., W.C.S.).
Annarita Di LorenzoFrom the Section of Nephrology (E.P.M., L.J., J.M., H.V.) and Department of Dermatology (L.M.M.), Yale School of Medicine, New Haven, CT; and Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT (A.D.L., K.F.H., A.K.L., W.C.S.).
Kara F HeldFrom the Section of Nephrology (E.P.M., L.J., J.M., H.V.) and Department of Dermatology (L.M.M.), Yale School of Medicine, New Haven, CT; and Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT (A.D.L., K.F.H., A.K.L., W.C.S.).
Amelia K LucianoFrom the Section of Nephrology (E.P.M., L.J., J.M., H.V.) and Department of Dermatology (L.M.M.), Yale School of Medicine, New Haven, CT; and Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT (A.D.L., K.F.H., A.K.L., W.C.S.).
Jonathan MelendezFrom the Section of Nephrology (E.P.M., L.J., J.M., H.V.) and Department of Dermatology (L.M.M.), Yale School of Medicine, New Haven, CT; and Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT (A.D.L., K.F.H., A.K.L., W.C.S.).
Leonard M MilstoneFrom the Section of Nephrology (E.P.M., L.J., J.M., H.V.) and Department of Dermatology (L.M.M.), Yale School of Medicine, New Haven, CT; and Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT (A.D.L., K.F.H., A.K.L., W.C.S.).
Heino VelazquezFrom the Section of Nephrology (E.P.M., L.J., J.M., H.V.) and Department of Dermatology (L.M.M.), Yale School of Medicine, New Haven, CT; and Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT (A.D.L., K.F.H., A.K.L., W.C.S.).
William C SessaFrom the Section of Nephrology (E.P.M., L.J., J.M., H.V.) and Department of Dermatology (L.M.M.), Yale School of Medicine, New Haven, CT; and Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT (A.D.L., K.F.H., A.K.L., W.C.S.).
Yale University · US

Funding

Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8M
Vascular Training GrantT32HL007950 · NHLBI · YALE UNIVERSITY · PI JEFFREY R. BENDER, Daniel Greif · 2000 to 2026
$9.6M
PHOSPHORYLATION AND ENDOTHELIAL NITRIC OXIDE PRODUCTIONR01HL064793 · NHLBI · YALE UNIVERSITY · PI SESSA, WILLIAM C · 2000 to 2016
$6.3M
INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDT32GM007324 · NIGMS · YALE UNIVERSITY · PI BENNETT, ANTON M · 1987 to 2022
$6.2M
Endothelial NOS by protein to protein interactionsR37HL061371 · NHLBI · YALE UNIVERSITY · PI SESSA, WILLIAM C · 2009 to 2017
$4.1M
Regulation of vascular remodeling &angiogenesis by NogoR01HL081190 · NHLBI · YALE UNIVERSITY · PI SESSA, WILLIAM C · 2005 to 2014
$4.1M
microRNA regulation of endothelial functionsR01HL096670 · NHLBI · YALE UNIVERSITY · PI SESSA, WILLIAM C · 2010 to 2013
$1.8M
The Role of Protein Palmitoylation in Endothelial Cell FunctionK08HL103831 · NHLBI · YALE UNIVERSITY · PI MARIN, ETHAN P · 2010 to 2014
$670k
NHLBI NIH HHS K08 HL103831NHLBI NIH HHS R01 HL064793NHLBI NIH HHS R01 HL081190NHLBI NIH HHS R01 HL096670NHLBI NIH HHS R37 HL061371NHLBI NIH HHS T32 HL007950NHLBI NIH HHS T32HL007950NIDDK NIH HHS P30 DK079310NIGMS NIH HHS T32 GM007324
6 · The paper itself

Abstract

objectivePalmitoylation, the reversible addition of the lipid palmitate to a cysteine, can alter protein localization, stability, and function. The ZDHHC family of protein acyl transferases catalyzes palmitoylation of numerous proteins. The role of ZDHHC enzymes in intact tissue and in vivo is largely unknown. Herein, we characterize vascular functions in a mouse that expresses a nonfunctional ZDHHC21 (F233Δ). APPROACH AND

resultsPhysiological studies of isolated aortae and mesenteric arteries from F233Δ mice revealed an unexpected defect in responsiveness to phenylephrine, an α1 adrenergic receptor agonist. In vivo, F233Δ mice displayed a blunted response to infusion of phenylephrine, and they were found to have elevated catecholamine levels and elevated vascular α1 adrenergic receptor gene expression. Telemetry studies showed that the F233Δ mice were tachycardic and hypotensive at baseline, consistent with diminished vascular tone. In biochemical studies, ZDHHC21 was shown to palmitoylate the α1D adrenoceptor and to interact with it in a molecular complex, thus suggesting a possible molecular mechanism by which the receptor can be regulated by ZDHHC21.

conclusionsTogether, the data support a model in which ZDHHC21 F233Δ diminishes the function of vascular α1 adrenergic receptors, leading to reduced vascular tone, which manifests in vivo as hypotension and tachycardia. This is to our knowledge the first demonstration of a ZDHHC isoform affecting vascular function in vivo and identifies a novel molecular mode of regulation of vascular tone and blood pressure.

Indexed as

HemodynamicsAcyltransferasesAdrenergic alpha-1 Receptor AgonistsAnimalsAortaBlood PressureDose-Response Relationship, DrugEpinephrineFibroblastsGenotypeHeart RateHEK293 CellsHumansHypotensionLipoylationMesenteric ArteriesAcyltransferasesAdrenergic alpha-1 Receptor AgonistsEpinephrineNorepinephrinePhenylephrineReceptors, Adrenergic, alpha-1Zdhhc21 protein, mouseadrenergic agonistsblood pressurecatecholaminespalmitatetachycardia

Identifiers

PMID26715683
PMCPMC4984414
OpenAlexW2199173863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.